Kornimate/medical-research-clean huggingface dataset:
single portable pulse-dose-conserving device vs. combined use of stationary and portable.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: introduction: portable oxygen devices simplify and facilitate patient therapy. this study was designed to compare oxygen saturation and patient satisfaction with a portable oxygen concentrator or with a combined system consisting of a fixed device with continuous flow oxygen dispensation and a portable device with pulse dispensation for ambulation. methods: this cross-over trial assessed 25 patients with copd (92% men; mean age 72.2 ± 7.4 years; mean fev 34.14 ± 12.51%) at four hospitals in madrid. all patients had previously used the combined system, consisting of a fixed oxygenation system and a portable system for ambulation, with 16 (64%) using stationary and portable concentrators and 9 (36%) using a stationary reservoir and portable liquid oxygen bag. oxygenation settings at rest and while walking were determined at baseline. patients were maintained on the previous combined system for one week and then switched to the portable oxygen concentrator for one week. mean spo2 over 24 hours was calculated by the software in the oximeter, and compliance was monitored


Eligibility criteria:
inclusion criteria: * aged 40-80 years * had been diagnosed with copd following the gold criteria * were receiving oxygen therapy using a fixed oxygenation system and a portable system for ambulation * without exacerbation during the previous month * agreed to participate exclusion criteria: * terminally ill * unable to understand spanish * had high oxygen flow at rest (\> 3 lpm) * high respiratory frequency at rest (\> 32 rpm) * were not achieving adequate o2 saturation levels during titration with the portable oxygen source * had previously been diagnosed with obstructive sleep apnea hypopnea syndrome (sahs) * were receiving mechanical ventilation.

Keywords: copd, portable concentrator, oxygen sources
a study of ly3462817 in participants with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the reason for this study is to see if the study drug ly3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * have a diagnosis of adult onset ra as defined by the 2010 american college of rheumatology (acr)/european league against rheumatism (eular) classification criteria for at least 3 months prior to screening * have moderately to severely active ra defined by the presence of ≥6 swollen joints (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening and baseline. the distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility * have at least 1 of the following: * positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at screening, or * previous radiographs documenting bony erosions in hands or feet consistent with ra * have c-reactive protein (crp) \>1.2 times upper limit of normal (uln) per the central laboratory at screening * demonstrated an inadequate response to, or loss of response or intolerance to: * at least 1 conventional synthetic disease-modifying antirheumatic drug (csdmard) treatment or * at least 1 biologic dmard/tsdmard treatment exclusion criteria: * class iv ra according to acr revised response criteria * have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of: * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline * have presence of confirmed cervical dysplasia * have had various types of infection within 3 months of screening or develops any of these infections before the randomization visit. * have any of the following: * human immunodeficiency virus (hiv) infection * current infection with hepatitis b virus (hbv) (i.e., positive for hepatitis b surface antigen and/or polymerase chain reaction (pcr) positive for hbv dna * current infection with hepatitis c virus (hcv) (i.e., positive for hcv rna) * active tuberculosis (tb) * have failed more than 2 biologic dmards (bdmards) or tsdmards (e.g. excluded if have received 2 bdmards and 1 tsdmard)
metformin effect on fracture healing in post-menopausal women

Conditions: Bone Fracture

Summary: study the effect of metformin drug on fracture healing of patients with high risk of delayed fracture healing or non-union and correlating this to serum irisin myokine level.

1. approval will be obtained from ethics committee of general organization of teaching hospitals and institutes and research ethics committee of faculty of pharmacy, damanhour university. 2. getting informed consent from all participants to take part in this study. 3. two groups each of 20 post-menopausal women with a bone fracture. one group will be treated randomly with metformin retard 850 mg once daily for two weeks then 850 mg twice daily. the other group will be untreated and served as control group. 4. venous blood samples will be taken from each patient before fracture stabilization and later for determination of serum irisin level with corresponding radiological evaluations. inclusion criteria: • age range from 55 to less than 65 years old with bone fracture. exclusion criteria: * age equal or less than 55 years * age equal or more than 65 years * unstable or hospitalized patients with heart failure * hepatic impairment * chronic kidney disease with egfr \<45 ml/minute/1.73 m2 * open fractures * pathological fractures * diabetic patients statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. methodology: * active human irisin elisa kit will be used. * bone-specific alkaline phosphatase bap * serum creatinine, serum albumin, prothrombin time. * fasting insulin, fasting blood glucose and calcium level. * bmi, weight, waist, waist-hip ratio, total cholesterol and low-density-lipoprotein cholesterol. * radiological scoring system will be used to evaluate the degree of new bone formation in the fracture line on anterior-posterior and lateral radiographs will be taken two months post stabilization.

Eligibility criteria:
inclusion criteria: * age range from 55 to less than 65 years old with bone fracture. exclusion criteria: * age equal or less than 55 years * age equal or more than 65 years * unstable or hospitalized patients with heart failure * hepatic impairment * chronic kidney disease with egfr \<45 ml/minute/1.73 m2 * open fractures * pathological fractures * diabetic patients

Keywords: bone fracture post-menopausal women metformin irisin
patient-reported outcomes measurement information system integration into rheumatology clinical practice

Conditions: Rheumatic Diseases

Summary: this study will examine the impact of providing patient-reported outcomes measurement information system (promis) scores to patients before appointments with their healthcare provider.


Eligibility criteria:
inclusion criteria for patients: * new and established patients seeking care at michigan medicine rheumatology clinics * patients should have access to the patient portal in michart patient portal * patients should have access to the internet at home to be able to complete the promis pro measures and study surveys online * patients should have completed promis pain, physical function, and sleep disturbance measures at least one day before their baseline appointment * at least one of the promis pro scores should be in the concerning zone (pain intensity ≥ 5, physical function ≤ 40, or sleep disturbance ≥ 60). exclusion criteria: * non-english speakers * under 18 years of age inclusion criteria for providers: * rheumatology health care providers, including clinicians and advanced practice providers at michigan medicine who are currently treating rheumatology patients exclusion criteria: * those not meeting the inclusion criteria

Keywords: health-related quality of life promis
a longitudinal study of function and participation in patients with stroke

Conditions: Stroke

Summary: a longitudinal study of function and participation in patients with stroke: an integrated brain imaging and biomechanical analysis

brain damage may lead to various motor deficits, which further influence the function and participation. cerebral vascular accident (cva) is the common disorder for acquired brain damage. neural network in patients with brain damage could also be used to determine their clinical behavior by identifying altered neural network associated with behavioral improvement. the investigators hypothesize that the level of brain image and biomechanical will change with time in patients with stroke. under this hypothesis, the measures of biomechanical change are correlated with neural changes. the aim of this study is to investigate the function and participation in patients with stroke evaluated by clinical measures, biomechanical, psychological, physiological and multimodal brain image. the primary goal of this study is to establish, evaluate and follow-up biomechanical- and image-based biomarkers for the impairment of function and participation information processing present in patients with stroke.

Eligibility criteria:
inclusion criteria: 1. patients with stroke 2. aged 20-80 years old 3. both ischemic stroke and hemorrhage exclusion criteria: 1. contraindication to mri, such as metallic implant 2. history of psychiatric disease 3. received botulinum toxin (btx-a) injection or surgery in recent six months 4. severe psychological impairments, such as mental retardation or severe communication problems 5. progressive disorders, such as neurodegenerative disease 6. active medical disease, such as infection

Keywords: stroke participation brain imaging biomechanical
evaluation of the long-term results of extended supra-basillary genioplasty of the "chin wing" type without bone graft

Conditions: Maxillofacial Abnormalities

Summary: the correction of maxillomandibular dysmorphoses, responsible for both functional discomfort (lip incompetence, ventilation disorders, periodontal disease) but also aesthetic, calls in particular for genioplasty, of which there are several techniques. one of these chin repositioning techniques, called "chin wing", cuts the bone to optimize the functional and aesthetic result. while all genioplasty techniques expose the risk of nerve damage and lack of bone consolidation, these parameters are only rarely addressed in the literature in the specific context of this extensive bone cutting. the objective of this work is to assess the satisfaction of patients who have benefited from chin advancement surgery using the "chin wing" technique.


Eligibility criteria:
inclusion criteria: * major subject (≥ 18 years old) * having undergone "chin wing" type genioplasty surgery in the maxillofacial surgery department of strasbourg between october 1, 2012 and june 30, 2022. * subject who has not expressed his opposition to the reuse of his data for scientific research purposes. exclusion criteria: * subject having expressed their opposition to the reuse of their data for scientific research purposes

Keywords: dysmorphoses maxillofacial abnormalities maxillomandibular lip incompetence ventilation disorders genioplasty
acupuncture for sleep disturbances in oef/oif veterans with post traumatic stress disorder

Conditions: Post Traumatic Stress Disorder; Sleep Disturbance

Summary: post traumatic stress disorder (ptsd) has emerged as a significant problem among troops returning from combat zones. a majority of these veterans will report difficulty maintaining or initiating sleep. the purpose of this research will be to conduct a prospective, randomized, wait list controlled, small scale feasibility study to examine if the use of an auricular acupuncture regimen improves quality of sleep for operation iraqi freedom/operation enduring freedom (oif/oef)veterans with ptsd receiving standard ptsd treatment. hypothesis: objective and subjective sleep disturbances and sleep quality will be improved in oif/oef veterans who receive auricular acupuncture in conjunction with standard ptsd therapy or standard therapy alone.


Eligibility criteria:
inclusion criteria: * age 18-50 years * male gender * veteran of oif/oef * comorbid mental health problems such as depression, anxiety are allowed * self-reported sleep disturbance (defined as having one or more of the following-sleep onset latency greater than 30 minutes, two or more awakenings per night, total sleep time less than six hours per night, presence of nightmares. * sleep disturbances must have started after a deployment exclusion criteria: * axis i mental disorders incompatible with active military service * history of moderate to severe traumatic brain injury * sleep apnea * current use of continuous positive airway pressure devices * significant co-morbid conditions (heart, lung, liver disease, etc.) * other treatment programs that involve cognitive processing therapy * no concurrent use of acupuncture during study * taking any anticoagulation medication * essential tremors

Keywords: post traumatic stress disorder sleep disturbance acupuncture
effect of low level laser therapy on pain occurring after insertion of an orthodontic device

Conditions: Bad Molar Teeth Arrangement Requiring Orthodontic Device

Summary: thus study consists of evaluating the effect of low level therapy on pain induced by insertion of an orthodontic device (the "quadhelix"). each day during the first seven days post procedure, the level of pain will be reported on an analogic visual scale. as secondary objectives, intake of antalgics and type of swallowed food (soft or tough) will also be daily registered.

patient will be randomized into one of the 3 following arms : * arm 1 (experimental) : administration of low level laser therapy just after insertion of the quadhelix. * arm 2 (sham procedure) : material necessary to perform low level laser therapy will be installed but the laser will not be activated. * arm 3 (no intervention): material necessary to perform low level laser therapy will not be installed

Eligibility criteria:
inclusion criteria: * children aged between 8 and 15 years old who need to receive an orthodontic device ("quadhelix) * informed consent form signed by parents who should be affiliated to french health insurance (french social security) exclusion criteria: * malignant facial tumor * not able to read or write correctly and thus not able to complete the questionnaire * allergic or intolerant to paracetamol * informed consent not obtained
the hemodynamic effects of sglt2i in acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: the main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (sglt2i) in patients admitted to the intensive care unit (icu) with acute decompensated heart failure.

the exact mechanism of cardiovascular benefit from sglt2i continues to be the source of further research. the investigators hypothesize that heart failure patients with acute decompensated heart failure will similarly benefit from the sglt2i-associated natriuresis and diuresis. this mechanism should improve invasive hemodynamics during an inpatient icu stay. this is a prospective, randomized controlled study to assess cardiac benefit of sglt2i in 40 consecutive patients admitted to university of chicago cardiac intensive care unit (ccu) advanced heart failure service. subjects will be randomized 1:1 to one of two routine care arms: treatment with an sglt2i \[dapagliflozin 10 mg daily\] or no sglt2i. after randomization, your sglt2i and heart failure care will be managed according to routine care, and the investigators will collect the subject's medical data. the patient's treating physician will be able to override randomization assignment if they determine that the assignment is not in the patient's best interest.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years old 2. heart failure reduced ejection fraction (hfref) of 40 or less 3. estimated glomerular filtration rate (egfr) \> 30milliliters(ml)/minute(min)/1.73 meter(m)2 4. admitted to ccu by advanced heart failure service for decompensated heart failure requiring continuous hemodynamic monitoring with a pulmonary artery catheter exclusion criteria: 1. diagnosis of type 1 diabetes mellitus 2. egfr \< 30ml/min/1.73m2 3. age \< 18 years old 4. jehovah's witnesses 5. diagnosis of group 1 pulmonary arterial hypertension 6. insulin requirement above standard low dose sliding scale 7. patients with a history of diabetic ketoacidosis (dka) 8. allergies to sglt2i medications 9. history of intolerance to sglt2i medications 10. patients listed for cardiac transplantation or on mechanical support 11. pregnant or breastfeeding

Keywords: sglt2i
separate and combined extrapancreatic effects of the incretin hormones

Conditions: Pancreatectomy; Hyperglycemia

Summary: the two gut-derived hormones, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. the hormones also exert effects outside the pancreas, but especially for gip, these are poorly investigated. because of this, only glp-1 based drugs (glp-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. nonetheless, a new drug is in clinical development: a combined gip-glp-1-receptor agonist (tirzepatide), which has shown better results than glp-1 alone. the mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of gip and glp-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.


Eligibility criteria:
inclusion criteria: * total pancreatectomy * caucasians * blood haemoglobin \>7 mmol/l for males and \>6.5 mmol/l for females exclusion criteria: * pancreatectomy within the last 3 months * ongoing chemotherapy or chemotherapy within the last 3 months * treatment with glp-1r agonists within the last 3 months * renal impairment (estimated by egfr \<60 ml/min/1.73 m2) and/or albuminuria * calcium related disease, hypo-/hyperthyroidism * known significant liver disease, alt or ast \>3 times normal value or inr outside normal range * severe arteriosclerotic heart disease or heart failure (nyha group iii or iv) * pregnancy and/or breastfeeding * use of more than 14 units of alcohol per week or abuse of narcotics * any condition that the investigator feels would interfere with trial participation
study with two different doses of desmopressin orally lyophilisate tablet with nocturnal enuresis

Conditions: Nocturnal Enuresis

Summary: this is multi-center, randomized, placebo-controlled, parallel-group, double-blind, dose-escalating clinical trial designed to assess the efficacy and safety of desmopressin orally lyophilisate for the treatment of nocturnal enuresis "with decreased nighttime urinary osmolality."


Eligibility criteria:
inclusion criteria: * diagnosed nocturnal enuresis with reduced nighttime urinary osmolality * age 6 or above but under 16 regardless of gender * out-patient * had 10 or more wet nights during the 14-day baseline period and at least 4 wet nights in each respective week * deemed healthy by the investigator * able to agree to and comply with fluid-intake restriction during the clinical trial and matters specified in the clinical trial protocol * consent from the pediatric patient's legally acceptable representative * demonstrate an understanding about this clinical trial after receiving an explanation corresponding to the prospective subject's intelligibility * show no possibility of being a nursing mother or pregnant, or becoming pregnant * if under drug or medical therapy other than desmopressin for treating nocturnal enuresis: able to discontinue such treatment exclusion criteria: * suffer from enuresis with an underlying disease * participated in another clinical trial within six months preceding consent * used an intranasal desmopressin in the past * presently undergoing a systemic antibiotic treatment, a treatment with an antidiuretic or a drug that affects urinary concentration, or a drug or medical therapy for overactive bladder * have an anomaly or a disease that may affect the oral absorption of drug products * hard to get cooperation from subject by school refusal, punishment or bullying * deemed by the investigator to be inappropriate to participate in this trial * unable to be placed on water-intake restriction starting from two hours before bedtime * evidence of hepatic, renal, cardiac, or pulmonary dysfunction
a game-based neurodevelopmental assessment for young children

Conditions: Neurodevelopmental Disorders; Autism Spectrum Disorder; Attention Deficit Hyperactivity Disorder; Dyslexia; Specific Learning Disorder; Child Development

Summary: the aim of this study is to evaluate a novel tablet game-based neurodevelopmental assessment tool for young children aged 3 to 8 years old. the study's main aims are: (1) to determine whether the novel tablet-game based assessment tool can accurately differentiate children's neurodevelopmental status based on their performance on the game and (2) assess the validity of the game-based neurodevelopment assessment tool. the study aims to recruit 590 children who are 'typically' developing and/or have a diagnosed neurodevelopmental disorder including attention deficit hyperactivity disorder (adhd), autism spectrum disorder (asd), specific learning disorder, or a communication disorder. all participants will complete the tablet game-based assessment which aims to assess a range of neuropsychological functions including attention, memory, language, motor, executive functions and social-emotional skills. parents/carers of participants will also complete a demographic questionnaire and the adaptive behaviour system - third edition (abas-3), which is a questionnaire that assesses a child's development. some participants will be re-tested on the tablet game-based assessment approximately 2 weeks after the first tablet game-based assessment to ensure the game's validity.


Eligibility criteria:
inclusion criteria: * 3 to 8 year old 'typically' developing children with no known neurodevelopmental disorder. or * 3 to 8 year old children with a diagnosed neurodevelopmental disorder, including attention deficit hyperactivity disorder (adhd), autism spectrum disorder (asd), specific learning disorder, or a communication disorder. all parents/caregivers and children must have a minimum level of english fluency required to complete the parent questionnaire and the game-based assessment. exclusion criteria: * children with medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.

Keywords: diagnostic test neurodevelopment medical technology